Amgen’s purchase of Abgenix
I got back from travels to find that Amgen had made an offer to purchase Agenix for $2.2 B . In June, I named four likely small-firm takeover targets by pharma on Pharma’s Cutting Edge. Abgenix and Neurocrine were the two I named without major obstacles against them. I named Amgen as Abgenix’ likely suitor. Neurocine remains unpaired for now and Pfizer is the likely suitor. As far as the proposed deal itself, I haven’t yet looked at the terms, but I’ll review the SEC filings and write a brief follow-up note.
